Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5

PHASE4TerminatedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

May 22, 2007

Primary Completion Date

December 10, 2007

Study Completion Date

December 10, 2007

Conditions
Kidney Diseases
Interventions
DRUG

Lanthanum carbonate

2250mg/day starting dose of lanthanum carbonate administered orally, in divided doses, with meals (500mg 750mg and 1000mg strengths)for 2 weeks; dose titration will occur based on serum phosphorus results not to exceed 3000mg/day.

Trial Locations (14)

3600

Ziekenhuis Zuid Oost Limburg, Genk

7000

Frederica Sygehus, Fredericia

22297

Dialysezentrum Barmbek, Hamburg

26127

nephrologische Schwerpunktpraxis, Oldenburg

49808

Nephrologisches Zentrum Emsland, Lingen

74076

Dialysezentrum Heilbronn, Heilbronn

78054

diabetologische Schwerpunktpraxis, Villingen-Schwenningen

A-6807

Landeskrankenhaus Feldkirch, Abteilung fur Nephrologie und dialyse, Feldkirch Tisis

A-4010

Krankenhaus Elisabethinen/Dialysestation, Linz

DK-4300

Holbaek Sykehus, Holbæk

88 00

Sygehus Viborg, Viborg

04178

Dialyse Leipzig, Leipzig

Unknown

University of Milan, San Paolo Hospital, Renal Division, Milan

7334 DZ

Gelre Ziekenhuizen, Apeldoorn

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY